Replies to post #162955 on Biotech Values

[jq1234]

That was example of flexibility in orphan drug exclusivity regulation. EMA approved both Fabrazyme and Replagal in 2001 with orphan drug exclusivity concurrently. I believe Replagal would have got approval along with Fabrazyme from FDA if advisory committee hadn't voted down Replagal mainly due to clinical data,